GI protection (preclinical): Reported cytoprotective effects on the gastrointestinal lining in animal models [2]
Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent
Results can vary quite a bit from person to person, but heres a general idea of what to expect: Initial Phase (First Month) Most people see the most dramatic results in the first month
Topical Versus Injectable: Which Causes More Issues
In laboratory settings, the ghk-cu peptide is studied for its relevance to cellular signaling pathways, metal-ion interaction models, and extracellular matrix research systems
While most people with well-managed asthma do fine, those with severe, unstable asthma might experience breathing difficulties during treatment